Results 161 to 170 of about 15,380 (223)

Current Systemic Treatment Options for Advanced Pancreatic Cancer-An Overview Article. [PDF]

Biomedicines
Domagała-Haduch M, Długaszek A, Gorzelak-Magiera A, Gisterek-Grocholska I.   +3 more
europepmc   +1 more source

Reprogrammierung des duktalen Pankreaskarzinoms unter FOLFIRINOX Therapie

Aufgrund des unzureichenden therapeutischen Ansprechens des duktalen Adenokarzinom des Pankreas (PDAC), besteht die dringende Notwendigkeit die molekularen Mechanismen zu entschlüsseln, die die Entstehung und das Fortschreiten des PDAC trotz Chemotherapie vorantreiben.
openaire   +1 more source

Reduced lipid metabolite abundance in human pancreatic cancer and matched serum samples following neoadjuvant FOLFIRINOX treatment. [PDF]

Metabolomics
Amrutkar M, Guttorm SJT, Labori KJ, Rootwelt H, Elgstøen KBP, Gladhaug IP, Verbeke CS.   +6 more
europepmc   +1 more source

Pegylated granulocyte colony-stimulating factor primary prophylaxis versus no prophylaxis in patients with unresectable pancreatic cancer treated with modified-FOLFIRINOX: a randomized, open-label, multicenter, phase 2 trial. [PDF]

EClinicalMedicine
Lee CK, Kim I, Seo DH, Park S, Kim M, Lee SH, Lee YJ, Kim JH, Kim CG, Choi HJ.   +9 more
europepmc   +1 more source

Phase I trial of stereotactic MR-guided online adaptive radiation therapy (SMART) for the treatment of oligometastatic or unresectable primary malignancies of the abdomen [PDF]

, 2018
Bradley, Jeffrey, Curcuru, Austen, DeWees, Todd, Green, Olga, Henke, Lauren, Kashani, Rojano, Michalski, Jeff, Mutic, Sasa, Olsen, Jeffrey, Parikh, Parag, Robinson, Clifford   +10 more
core   +2 more sources

Chemotherapy for Locally Advanced Pancreatic Cancer: The Dilemma of David Versus Goliath After NEOPAN. [PDF]

J Clin Oncol
Nichetti F, Procaccio L, Lonardi S, Bergamo F.   +3 more
europepmc   +1 more source

Body mass index has no impact on complications and mortality for patients with stage IV pancreatic ductal adenocarcinoma. [PDF]

Transl Gastroenterol Hepatol
Bryant R, Darnell H, Hall M, Karnik K, McQuerry K, Plentz RR.   +5 more
europepmc   +1 more source

The management of metastatic pancreatic cancer: expert discussion and recommendations from the 14th ESMO/World Congress on Gastrointestinal Cancer, Barcelona, 2012 [PDF]

, 2017
Arber, N., Berlin, J. D., Büchler, M. W., Cervantes, A., Ciardiello, F., Dicato, M., Douillard, J. Y., Ducreux, M., Grothey, A., Haller, D., Haustermans, K., Heinemann, V., Hidalgo, M., Labianca, R., Li, J., Marshall, J. L., Nordlinger, B., O'Reilly, E. M., Roth, A., Rougier, P., Ryan, D., Schmiegel, W., Schmoll, H. J., Seufferlein, T., Sobrero, A., Tabernero, J., Tempero, M., Van Cutsem, E., Van Laethem, J. L., Verslype, C., Ychou, M., Zalcberg, J.   +31 more
core  

-Paclitaxel Plus Gemcitabine Versus Gemcitabine in Patients with Metastatic Pancreatic Adenocarcinoma: Canadian Subgroup Analysis of the Phase 3 MPACT Trial [PDF]

core   +1 more source

Advanced Human Immune Cell-Organoid Co-Cultures for Functional Testing of Cancer Nanovaccines. [PDF]

Adv Sci (Weinh)
Ferreira N, Agorku D, Rosa A, Roosz J, Christ L, Anderle N, Kulkarni A, Hussein A, Sayedipour SS, Luna OF, Legler T, Ströbel P, Albericio F, Cruz L, Beckhove P, Loskill P, Alves F, Markus MA, Ramos-Gomes F.   +18 more
europepmc   +1 more source